Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Dragonfly Therapeutics Inc. currently faces 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners, indicating that each case is being reviewed by a different individual. Furthermore, the prosecution activity spans 2 distinct art units, suggesting a diversification in the technical classification of the company's current patent filings.
The busiest examiner for this portfolio is PRIEST, JESSICA MARIE, who is responsible for 1 busiest examiner pending office action. Since there are 2 pending office actions in total, the workload is shared between the involved examiners. This distribution means that the legal team must manage separate prosecution tracks, each with its own set of examiner preferences and art unit standards.
For practitioners, the involvement of 2 distinct art units within the Biotechnology & Pharmaceuticals sector requires a strategy that accounts for different procedural norms. While PRIEST, JESSICA MARIE handles 1 busiest examiner pending office action, the other action is managed by a different examiner. This variety suggests that the legal team must remain adaptable to the specific feedback and examination styles across the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18107292 | MULTISPECIFIC BINDING PROTEINS TARGETING CEA | HUYNH, PHUONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18107292 | MULTISPECIFIC BINDING PROTEINS TARGETING CEA | HUYNH, PHUONG N | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18366876 | PROTEINS BINDING NKG2D, CD16, AND CEACAM5 | PRIEST, JESSICA MARIE | 1642 | §112 | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18107292 | MULTISPECIFIC BINDING PROTEINS TARGETING CEA | HUYNH, PHUONG N | 1641 | §103§112 | Non-Final OA | — | Pending | Feb 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial